Mirum Pharmaceuticals ( MIRM ) just reported its 4Q, its full year topline clocking in at $521 million , up 55% from the prior year. Though the quarter's net income disappointed, the call cemented a banner year and providedSean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. He has also writte ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure N.V. is based in Amsterdam and focuses on developing and commercializing gene therapies for severe diseases, particularly Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250%, from $13.66 to $47.50 per share, following positive statements [3]. - On November 3, 2025, it was revealed that the FDA agreement on study design was not finalized, causing a stock price drop of over 49%, from $67.69 to $34.29 per share [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [4][6]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a company listed on NASDAQ under the ticker VTGN [4]. - The company is developing fasedienol, an investigational pherine candidate aimed at treating social anxiety disorder [6]. Group 2: Legal Investigation - The law firm Faruqi & Faruqi is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [4][8]. Group 3: Trial Results and Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, reporting no statistically significant improvement in anxiety reduction compared to placebo [7]. - Following the announcement, Vistagen's stock price fell by $3.50, or 80.27%, closing at $0.86 [7]. Group 4: Investor Communication - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [9].

Leonard said the company’s glioblastoma (GBM) business remains core. In 2025, NovoCure saw active patient growth across major markets, driven primarily outside the U.S. He cited year-over-year active patient growth of 10% in Germany, 19% in France and 29% in Japan, along with 4% growth in the U.S., which he said had been flat in recent years. For 2026, management expects growth rates to stabilize in the “low to mid-single digit” range as markets mature, with modest first-year contributions expected from lau ...

Zai Lab (NasdaqGM:ZLAB) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristine Chiou - SVP of Investor RelationsHaichong Lin - AssociateJonathan Chang - Senior Managing Director of Emerging OncologyJosh Smiley - President and COOLi Watsek - DirectorMichael Yee - Global Head of Biotechnology ResearchRafael Amado - President and Head of Global Research and DevelopmentSamantha Du - Founder, Chairperson, and CEOYajing Qian - CFOConference Call ParticipantsAnupam Rama - Managing Direct ...

Phathom Pharmaceuticals (NasdaqGS:PHAT) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnnabel Samimy - Managing Director of BioPharma and BiotechnologyAnthea Li - Senior Associate in Biotechnology Equity ResearchEric Sciorilli - Head of Investor RelationsMartin Auster - Managing DirectorMin Lee - Biotech Equity Research AssociateSanjeev Narula - Chief Financial and Business OfficerSteven Basta - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Resear ...

Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAshleigh Acker - Biotechnology Equity Research AssociateErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven Burke - Chief Medical OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystMichael Cherny - ...

Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven K. Burke - Senior Vice President, Chief Research and Development OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystManagi Nassar - Senior Equity ...

BeOne Medicines (NasdaqGS:BGNE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAaron Rosenberg - CFOAmit Aggarwal - Chief Medical Officer of HematologyDan Maller - VP of Investor RelationsJohn V. Oyler - Co-Founder, Chairman and CEOLai Wang - President and Global Head of Research & DevelopmentMark Lanasa - SVP and Chief Medical OfficerMatt Shaulis - General Manager of North AmericaSean Laaman - Executive DirectorXiaobin Wu - President and COOZhihong Chen - Managing DirectorNone - Co ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...